Elamipretide - Stealth BioTherapeutics

Drug Profile

Elamipretide - Stealth BioTherapeutics

Alternative Names: Bendavia; ELA 4; MTP 131; Ocuvia; SBT-31; SPI-31; SS-31

Latest Information Update: 19 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stealth Peptides
  • Developer Stealth BioTherapeutics
  • Class Eye disorder therapies; Ischaemic heart disorder therapies; Oligopeptides; Peptides; Small molecules
  • Mechanism of Action Free radical scavengers; Mitochondrial permeability transition pore inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mitochondrial myopathies
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Mitochondrial myopathies
  • Phase II/III Barth syndrome
  • Phase II Acute kidney injury; Corneal disorders; Heart failure; Leber's hereditary optic atrophy; Mitochondrial disorders; Reperfusion injury
  • Phase I/II Diabetic macular oedema; Dry age-related macular degeneration
  • No development reported Chronic heart failure; Diabetes mellitus; Eye-Disorders; Neurodegenerative disorders

Most Recent Events

  • 06 Mar 2018 Stealth BioTherapeutics completes enrolment in the TAZPOWER phase II/III trial for Barth Syndrome in USA
  • 18 Dec 2017 Elamipretide - Stealth BioTherapeutics receives Fast Track designation for Barth syndrome [SC,Injection] (In adults, In adolescents, In children, In the elderly) in USA before December 2017
  • 18 Dec 2017 Elamipretide - Stealth BioTherapeutics receives Fast Track designation for Leber's hereditary optic atrophy [Ophthalmic,Drops] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top